Literature DB >> 16133635

[Infliximab. Role in the treatment of psoriasis].

R Mössner1, K Reich.   

Abstract

Psoriasis is one of the immune-mediated inflammatory diseases (IMIDs), in whose pathogenesis Th1-mediated immune responses are considered crucial. Infliximab is a chimeric monoclonal antibody directed against the Th1-cytokine TNF-alpha that has already been approved for the therapy of psoriatic arthritis (in combination with methotrexate). In clinical studies, infliximab has proved safe and effective in treating plaque-type psoriasis. In 80% of treated patients, the Psoriasis Area and Severity Index (PASI) decreased after 10 weeks by > or =75%. Infliximab is expected to be approved as second-line therapy in Germany this year for the treatment of psoriasis vulgaris.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16133635     DOI： 10.1007/s00105-005-1005-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  23 in total

1.  Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab).

Authors:  K Schmick; J Grabbe
Journal:  Br J Dermatol       Date:  2004-02       Impact factor: 9.302

Review 2.  Quality-of-life issues in psoriasis.

Authors:  Rita Mukhtar; Jane Choi; John Y M Koo
Journal:  Dermatol Clin       Date:  2004-10       Impact factor: 3.478

3.  Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

Authors:  Lennart T H Jacobsson; Carl Turesson; Anders Gülfe; Meliha C Kapetanovic; Ingemar F Petersson; Tore Saxne; Pierre Geborek
Journal:  J Rheumatol       Date:  2005-07       Impact factor: 4.666

4.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

Authors:  U Chaudhari; P Romano; L D Mulcahy; L T Dooley; D G Baker; A B Gottlieb
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

5.  Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

Authors:  S R Feldman; K B Gordon; M Bala; R Evans; S Li; L T Dooley; C Guzzo; K Patel; A Menter; A B Gottlieb
Journal:  Br J Dermatol       Date:  2005-05       Impact factor: 9.302

Review 6.  Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis.

Authors:  Mike J Peters; Irene E van der Horst-Bruinsma; Ben A Dijkmans; Michael T Nurmohamed
Journal:  Semin Arthritis Rheum       Date:  2004-12       Impact factor: 5.532

7.  Restraining mycobacteria: role of granulomas in mycobacterial infections.

Authors:  B M Saunders; A M Cooper
Journal:  Immunol Cell Biol       Date:  2000-08       Impact factor: 5.126

8.  Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.

Authors:  A Di Sabatino; R Ciccocioppo; B Cinque; D Millimaggi; R Morera; L Ricevuti; M G Cifone; G R Corazza
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

Authors:  Alice B Gottlieb; Robert Evans; Shu Li; Lisa T Dooley; Cynthia A Guzzo; Daniel Baker; Mohan Bala; Colleen W Marano; Alan Menter
Journal:  J Am Acad Dermatol       Date:  2004-10       Impact factor: 11.527

10.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.